Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Respiratory Review of 2010: Pneumonia

호흡기내과 의사를 위한 폐렴 리뷰

  • Kim, Yun-Seong (Department of Internal Medicine, Pusan National University School of Medicine)
  • 김윤성 (부산대학교 의학전문대학원 내과학교실)
  • Received : 2010.05.26
  • Accepted : 2010.05.26
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Pneumonia represents a spectrum of diseases that range from community-acquired to health care-associated pneumonia. Despite advances in diagnosis, antimicrobial therapy, and supportive care, pneumonia remains an important cause of morbidity and mortality, particularly in elderly patients and in those with significant comorbidities. Community-acquired pneumonia (CAP) is the leading cause of death from infectious disease in Korea. This article provides a synopsis of recent studies regarding various types of pneumonia, with a focus on CAP.

Keywords

References

  1. Song JH, Jung KS, Kang MW, Kim DJ, Pai H, Suh GY, et al. Treatment guidelines for community-acquired pneumonia in Korea: an evidence-based approach to appropriate antimicrobial therapy. Tuberc Respir Dis 2009;67:281-302. https://doi.org/10.4046/trd.2009.67.4.281
  2. Korea National Statistical Office. Annual report on the cause of death statistics 2007: nationwide. Daejeon: Korea National Statistical Office; 2007.
  3. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin- based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the Pro- HOSP randomized controlled trial. JAMA 2009;302: 1059-66. https://doi.org/10.1001/jama.2009.1297
  4. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, et al. Increasing prevalence of multidrug- resistant Streptococcus pneumoniae in the United- States. N Engl J Med 2000;343:1917-24. https://doi.org/10.1056/NEJM200012283432603
  5. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008;47:735-43. https://doi.org/10.1086/591126
  6. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, HuberPR, Tamm M, et al. Effect of procalcitonin- guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600-7. https://doi.org/10.1016/S0140-6736(04)15591-8
  7. Menendez R, Torres A, Zalacain R, Aspa J, Martin-Villasclaras JJ, Borderias L, et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005;172:757-62. https://doi.org/10.1164/rccm.200411-1444OC
  8. Menendez R, Martinez R, Reyes S, Mensa J, Filella X, Marcos MA, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009;64:587-91. https://doi.org/10.1136/thx.2008.105312
  9. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify lowrisk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50. https://doi.org/10.1056/NEJM199701233360402
  10. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82. https://doi.org/10.1136/thorax.58.5.377
  11. Capelastegui A, Espana PP, Quintana JM, Areitio I, Gorordo I, Egurrola M, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006;27:151-7. https://doi.org/10.1183/09031936.06.00062505
  12. Ewig S, Kleinfeld T, Bauer T, Seifert K, Schafer H, Goke N. Comparative validation of prognostic rules for community- acquired pneumonia in an elderly population. Eur Respir J 1999;14:370-5.
  13. Deng JC, Standiford TJ. The systemic response to lung infection. Clin Chest Med 2005;26:1-9. https://doi.org/10.1016/j.ccm.2004.10.009
  14. Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006;10:R96. https://doi.org/10.1186/cc4443
  15. Niederman MS. Recent advances in community-acquired pneumonia: inpatient and outpatient. Chest 2007;131:1205-15. https://doi.org/10.1378/chest.06-1994
  16. Lin MC, Chen YC, Wu JT, Ko YC, Wang CC. Diagnostic and prognostic values of pleural fluid procalcitonin in parapneumonic pleural effusions. Chest 2009;136:205- 11. https://doi.org/10.1378/chest.08-1134
  17. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. https://doi.org/10.1056/NEJMoa063070
  18. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6. https://doi.org/10.1164/rccm.200611-1630OC
  19. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-16. https://doi.org/10.1001/jama.2008.717
  20. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303. https://doi.org/10.1136/bmj.320.7245.1297
  21. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23. https://doi.org/10.1016/S0140-6736(98)10019-3
  22. Sin DD, Tashkin D, Zhang X, Radner F, Sjobring U, Thoren A, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009;374:712-9. https://doi.org/10.1016/S0140-6736(09)61250-2
  23. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169:219-29. https://doi.org/10.1001/archinternmed.2008.550
  24. Ek A, Larsson K, Siljerud S, Palmberg L. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy 1999;54:691-9. https://doi.org/10.1034/j.1398-9995.1999.00087.x
  25. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-7. https://doi.org/10.1183/09031936.00193908
  26. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-41. https://doi.org/10.1001/jama.275.2.134
  27. Lisboa T, Blot S, Waterer GW, Canalis E, de Mendoza D, Rodriguez A, et al. Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest 2009;135:165-72. https://doi.org/10.1378/chest.08-1216
  28. Venditti M, Falcone M, Corrao S, Licata G, Serra P. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009;150:19-26. https://doi.org/10.7326/0003-4819-150-1-200901060-00005
  29. Obaro SK, Monteil MA, Henderson DC. The pneumococcal problem. BMJ 1996;312:1521-5. https://doi.org/10.1136/bmj.312.7045.1521
  30. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009;180:48-58. https://doi.org/10.1503/cmaj.080734
  31. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-77. https://doi.org/10.1001/archinte.1994.00420230051007
  32. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008;1:CD000422.
  33. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005;366:1165-74. https://doi.org/10.1016/S0140-6736(05)67339-4
  34. Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C, et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989;139:877-84. https://doi.org/10.1164/ajrccm/139.4.877
  35. Kollef MH. Ventilator-associated pneumonia. A multivariate analysis. JAMA 1993;270:1965-70. https://doi.org/10.1001/jama.270.16.1965
  36. Vincent JL. Nosocomial infections in adult intensivecare units. Lancet 2003;361:2068-77. https://doi.org/10.1016/S0140-6736(03)13644-6
  37. Nardino RJ, Vender RJ, Herbert PN. Overuse of acidsuppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118-22.
  38. Pham CQ, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother 2006;40:1261-6. https://doi.org/10.1345/aph.1G703
  39. Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther 2003; 17:1503-6. https://doi.org/10.1046/j.1365-2036.2003.01600.x
  40. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital- acquired pneumonia. JAMA 2009;301:2120-8. https://doi.org/10.1001/jama.2009.722
  41. Qadeer MA, Richter JE, Brotman DJ. Hospital-acquired gastrointestinal bleeding outside the critical care unit: risk factors, role of acid suppression, and endoscopy findings. J Hosp Med 2006;1:13-20. https://doi.org/10.1002/jhm.10
  42. Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children-- Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009;58:400-2.
  43. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, Bautista E, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009;361: 680-9. https://doi.org/10.1056/NEJMoa0904252
  44. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009;302:1896-902. https://doi.org/10.1001/jama.2009.1583